Controlled release of growth factors and signaling molecules for promoting angiogenesis

Patent metadata

Field	Value
Publication number	US-9539309-B2
Application number	US-201514679723-A
Country	US
Kind code	B2
Filing date	Apr 6, 2015
Priority date	May 30, 2008
Publication date	Jan 10, 2017
Grant date	Jan 10, 2017

Abstract

The present invention comprises compositions, methods, and devices for delivering angiogenic factors and signaling molecules to a target tissue, and controlling the release of these factors and signaling molecules to spatially and temporally restrict their release and dissemination, for the purpose of promoting angiogenesis in target tissues wherein increased blood supply is needed.

First claim

What is claimed is:

1. A device comprising an alginate hydrogel scaffold composition comprising N—[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT) and a vascular endothelial growth factor (VEGF), wherein the VEGF comprises VEGF 121 , VEGF 145 , VEGF 165 , VEGF 189 , or VEGF 206 , and wherein the alginate hydrogel scaffold composition temporally controls the release of the DAPT and the VEGF from the alginate hydrogel scaffold composition.

2. The device of claim 1 , wherein the DAPT is released from the alginate hydrogel scaffold composition at a first rate and the VEGF is released from the alginate hydrogel scaffold composition at a second rate, and wherein the second rate is slower than the first rate.

3. The device of claim 1 , wherein the VEGF is covalently linked to the alginate hydrogel scaffold composition.

4. The device of claim 1 , wherein the VEGF is non-covalently linked to the alginate hydrogel scaffold composition.

5. The device of claim 1 , wherein the scaffold composition degrades at a predetermined rate based on a physical parameter selected from the group consisting of temperature, pH, hydration status, and porosity.

6. The device of claim 1 , wherein the DAPT is released before the VEGF from the alginate hydrogel scaffold composition.

7. The device of claim 1 , wherein the alginate hydrogel scaffold composition comprises nanopores.

8. The device of claim 1 , wherein the DAPT is released from the alginate hydrogel scaffold composition within 1 to 3 days.

9. The device of claim 1 , wherein the VEGF is released from the alginate hydrogel scaffold composition within 7 to 60 days.

10. The device of claim 1 , wherein the alginate hydrogel scaffold composition comprises a molar ratio of 1:1 to 1:200 for VEGF 165 to DAPT.

11. The device of claim 1 , wherein the alginate hydrogel scaffold composition comprises a molar ratio of 1:31 for VEGF 165 to DAPT.

12. The device of claim 1 , wherein the alginate hydrogel scaffold composition further comprises platelet-derived growth factor (PDGF).

13. The device of claim 12 , wherein the PDGF comprises PDGF-BB.

14. The device of claim 13 , wherein the alginate hydrogel scaffold composition comprises a molar ratio of 1:1 to 1:200 for PDGF-BB to DAPT.

15. The device of claim 14 , wherein the alginate hydrogel scaffold composition comprises a molar ratio of 1.8:31 for PDGF-BB to DAPT.

Assignees

• Harvard College

Inventors

• Cao Lan
• Mooney David J

Classifications

• A61L2300/414

  Growth factors · CPC title

• A61K38/05

  Dipeptides · CPC title

• A61L27/54

  Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title

• A61K38/1858

  Platelet-derived growth factor [PDGF] · CPC title

• A61K38/1866 Primary

  Vascular endothelial growth factor [VEGF] · CPC title